TARSUS PHARMACEUTICALS, INC. Effective Income Tax Rate Reconciliation, Other Adjustments, Amount
TARSUS PHARMACEUTICALS, INC. (TARS) reported Effective Income Tax Rate Reconciliation, Other Adjustments, Amount of $37.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-25.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationOtherAdjustments · last filed 2025-02-25
- TARSUS PHARMACEUTICALS, INC. effective income tax rate reconciliation, other adjustments, amount for fiscal 2024 was $37.00K, a 208.33% increase from fiscal 2023.
- TARSUS PHARMACEUTICALS, INC. effective income tax rate reconciliation, other adjustments, amount for fiscal 2023 was $12.00K, a 90.48% decline from fiscal 2022.
- TARSUS PHARMACEUTICALS, INC. effective income tax rate reconciliation, other adjustments, amount for fiscal 2022 was $126.00K.
- TARSUS PHARMACEUTICALS, INC. effective income tax rate reconciliation, other adjustments, amount for fiscal 2021 was -$50.00K, a 272.41% decline from fiscal 2020.
| Period end | Effective Income Tax Rate Reconciliation, Other Adjustments, Amount 12 month | Effective Income Tax Rate Reconciliation, Other Adjustments, Amount 12 month as first filed |
|---|---|---|
| 2024-12-31 | $37.00K 10-K · filed 2025-02-25 | |
| 2023-12-31 | $12.00K 10-K · filed 2025-02-25 | |
| 2022-12-31 | $126.00K 10-K · filed 2025-02-25 | $212.00K 10-K · filed 2023-03-17 |
| 2021-12-31 | -$50.00K 10-K · filed 2023-03-17 | |
| 2020-12-31 | $29.00K 10-K · filed 2022-03-14 | $119.00K 10-K · filed 2021-03-31 |
| 2019-12-31 | $4.00K 10-K · filed 2021-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |